On Wednesday, Following Stocks were among the “Top 50 Losers” of U.S. Stock Market: Cytori Therapeutics, Inc. (NASDAQ:CYTX), RMG Networks Holding Corporation (NASDAQ:RMGN), DragonWave Inc (NASDAQ:DRWI), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
Cytori Therapeutics, Inc. (NASDAQ:CYTX), with shares declined -8.33%, closed at $1.21.
RMG Networks Holding Corporation (NASDAQ:RMGN), with shares dropped -8.29%, settled at $1.77.
DragonWave Inc (NASDAQ:DRWI), with shares dipped -9.65%, and closed at $0.590.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), plummeted -8.19%, and closed at $4.37.
Latest NEWS regarding these Stocks are depicted underneath:
Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Last week, on the same day, i.e., Thursday, Cytori Therapeutics, Inc. (CYTX), declared its fourth quarter and year end 2014 business and financial results. By virtue of widespread cost reduction initiatives implemented in 2014, Cytori achieved substantial influence in tapering operating cash burn. Q4 operating cash burn reduced to $4.9 million, down from $7.2 million in Q3 2014, and $9.5 million a year ago in Q4 2013. We will continue to work to drive down expenses and raise operating efficiencies, and expect to deliver year-over-year operating cash burn savings of about $10 million from 2013 to 2015. Specifically, the predictable operating cash burn in 2015 will be about $25 million for the year, down from $35 million in 2013. 2014 cost reduction efforts have comprised of eliminating and consolidating certain commercial and development activities and containing outside professional services. Going forward, additional cost reductions will be derived primarily from changes to our fixed costs and physical locations. These efforts will be complemented by diligently working with Cytori’s lenders to restructure and extend debt obligations.
Cytori achieved total proceeds for the year and fourth quarter ended December 31, 2014 of $7.6 million and $3.8 million, respectively, contrast to $12.2 million and $3.5 million, respectively, for the same periods in 2013. Total net loss allocable to ordinary stock holders was $38.5 million in 2014 contrast with $26.2 million in 2013. Cytori ended the year with $14.6 million of cash and cash equivalents.
2014 Financial Performance explains Cash and debt balances at December 31, 2014 of about $14.6 million and $25.4 million, respectively.
Q4 and full-year 2014 operating cash burn of $4.9 million and $30.3 million, respectively, contrast to $9.5 million and $34.6 million for the same periods in 2013.
Q4 and full-year 2014 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, of a profit of $69 thousand and a loss of $3.8 million, respectively, contrast to a loss of $0.8 million and a loss of $4.5 million for the same periods in 2013.
Q4 and full-year 2014 contract proceed of $1.3 million and $2.6 million, respectively, contrast to $0.8 million and $3.3 million for the same periods in 2013.
Q4 and full-year 2014 net loss allocable to ordinary stock holders was $6.9 million (or $0.08 per share) and $38.5 million (or $0.48 per share), respectively, contrast to $10 million (or $0.14 per share) and $26.2 million (or $0.39 per share) for the same periods in 2013.
Cytori Therapeutics is a late stage cell therapy corporation developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.
RMG Networks Holding Corporation (NASDAQ:RMGN)
RMG Networks Holding Corporation (RMGN), declared its initial financial results for its Q4 and full year ended December 31, 2014.
Robert Michelson, Chief Executive Officer, commented, “We executed well in the fourth quarter and our results are encouraging as we expect strong sequential growth in both adjusted proceed and adjusted EBITDA. In addition, we continued to successfully implement the planned initiatives that we expect will further establish the platform for long-term success.”
“Since the third quarter, we have brought to market the first three products in our ‘Six New Products in Six Months’ initiative, strengthening our product portfolio with unique solutions,” continued Mr. Michelson. “In addition, our sales team has significantly bolstered the number of seven-figure deals in our pipeline. This steadfast focus on product innovation, global coordination and sales team productivity has begun to drive the momentum that we believe will deliver accelerated growth starting later this year.”
RMG Networks will release its full financial results for the fourth quarter and full-year 2014 before the market opens on Thursday, March 19, 2015. Administration will host a conference call to talk about these results on Thursday, March 19, 2015 at 9 a.m. ET.
RMG Networks Holding Corporation provides enterprise-class digital signage solutions and media applications. It offers a suite of products, counting media services, proprietary software, software-embedded hardware, maintenance and support service.
DragonWave Inc. (NASDAQ:DRWI)
Formerly on March 5, DragonWave Inc. (DRWI), a leading global supplier of packet microwave radio systems for mobile and access networks, declared that it received a notice from The NASDAQ Stock Market that the Corporation is not in compliance with NASDAQ’s Listing Rule 5450(a)(1), as the minimum bid price of DragonWave’s ordinary shares has closed below US$1.00 per share for 30 successive business days. The notification of noncompliance has no immediate effect on the listing or trading of DragonWave’s ordinary shares on the NASDAQ Global Market under the symbol “DRWI”.
The Corporation has 180 days, or until August 31, 2015, to achieve compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of DragonWave’s ordinary shares must meet or exceed US$1.00 per share for a minimum of 10 successive business days during this 180-day grace period.
If the Corporation does not regain compliance with the Rule by August 31, 2015, the Corporation may be eligible for an additional 180 calendar day compliance period. To qualify, the Corporation would need to transfer the listing of its ordinary shares to The NASDAQ Capital Market, offered that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement. The Corporation’s failure to regain compliance could result in delisting of its ordinary shares on NASDAQ.
DragonWave Inc. provides high-capacity packet microwave solutions that drive IP networks worldwide. Its carrier-grade point-to-point packet microwave systems transmit broadband voice, video, and data to meet bandwidth requirements.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
On Wednesday, Anthera Pharmaceuticals, Inc. (ANTH), declared the pricing of an underwritten public offering of 5,555,556 shares of its ordinary stock, offered at a price of $4.50 per share. The Corporation estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be $25 million. The offering is predictable to close on or about March 23, 2015, subject to customary closing conditions. In addition, Anthera has granted the underwriter a 30-day option to purchase up to an additional 833,333 shares of ordinary stock to cover over-allotments, if any. The Corporation intends to use the net proceeds from the offering for clinical research and development and general corporate purposes.
Piper Jaffray & Co. is acting as sole underwriter in the offering. The Trout Group, LLC has acted as advisor to the Corporation.
Anthera Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
